This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Nicholas J. Fiumara, MD
Boston and Tufts Universities Schools of Medicine Harvard Medical School

JAMA. 1986;256(11):1443.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Markovitz and associates¹ at the University of Rochester Department of Dermatology and Medicine again call to the attention of the practicing physician the inadequacy of the guidelines of the Centers for Disease Control (CDC) for the treatment of infectious syphilis in the primary and secondary stages and the early latent stage of less than one year's duration.² They had the unfortunate experience, as others have had,³ of treating a patient with secondary syphilis with 2.4 million units of penicillin G benzathine intramuscularly in a single session, according to the CDC guidelines, only to have the patient relapse with secondary syphilis and a basilar meningitis three months after treatment.

Dr Markovitz refers to our studies on the treatment of primary and secondary syphilis with 2.4 million units of penicillin G benzathine intramuscularly each week for two consecutive weeks, for a total of 4.8 million units. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?